A top-down approach for construction of hybrid polymer-virus gene delivery vectors
- PMID: 20117154
- DOI: 10.1016/j.jconrel.2010.01.031
A top-down approach for construction of hybrid polymer-virus gene delivery vectors
Abstract
Safe and efficient delivery of therapeutic nucleic acids remains the primary hurdle for human gene therapy. While many researchers have attempted to re-engineer viruses to be suited for gene delivery, others have sought to develop non-viral alternatives. We have developed a complementary approach in which viral and synthetic components are combined to form hybrid nanoparticulate vectors. In particular, we complexed non-infectious retrovirus-like particles lacking a viral envelope protein, from Moloney murine leukemia virus (M-VLP) or human immunodeficiency virus (H-VLP), with poly-L-lysine (PLL) or polyethylenimine (PEI) over a range of polymer/VLP ratios. At appropriate stoichiometry (75-250 microg polymer/10(6) VLP), the polymers replace the function of the viral envelope protein and interact with the target cell membrane, initiate cellular uptake and facilitate escape from endocytic vesicles. The viral particle, once in the cytosol, efficiently completes its normal infection process including integration of viral genes with the host genome as demonstrated by long-term (at least 5 weeks) transgene expression. In addition, hybrid vectors comprising H-VLP were shown to be capable of infecting non-dividing cells.
Copyright 2010 Elsevier B.V. All rights reserved.
Similar articles
-
Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors.Nat Genet. 1997 Nov;17(3):314-7. doi: 10.1038/ng1197-314. Nat Genet. 1997. PMID: 9354796
-
Characterization of an alternative packaging system derived from the cat RD114 retrovirus for gene delivery.J Gene Med. 2009 Aug;11(8):664-9. doi: 10.1002/jgm.1351. J Gene Med. 2009. PMID: 19507185
-
A comparison of the effectiveness of cationic polymers poly-L-lysine (PLL) and polyethylenimine (PEI) for non-viral delivery of plasmid DNA to bone marrow stromal cells (BMSC).Eur J Pharm Biopharm. 2007 Mar;65(3):388-97. doi: 10.1016/j.ejpb.2006.11.026. Epub 2006 Dec 13. Eur J Pharm Biopharm. 2007. PMID: 17240127
-
Viral vectors for gene therapy.Pharmacol Ther. 1998 Oct;80(1):35-47. Pharmacol Ther. 1998. PMID: 9804053 Review.
-
Towards safe, non-viral therapeutic gene expression in humans.Nat Rev Genet. 2005 Apr;6(4):299-310. doi: 10.1038/nrg1577. Nat Rev Genet. 2005. PMID: 15761468 Review.
Cited by
-
Intracellular trafficking of hybrid gene delivery vectors.J Control Release. 2015 Jun 10;207:120-30. doi: 10.1016/j.jconrel.2015.04.015. Epub 2015 Apr 14. J Control Release. 2015. PMID: 25883029 Free PMC article.
-
Efficient in vitro gene delivery by hybrid biopolymer/virus nanobiovectors.J Control Release. 2014 Oct 28;192:40-6. doi: 10.1016/j.jconrel.2014.06.060. Epub 2014 Jul 8. J Control Release. 2014. PMID: 25009978 Free PMC article.
-
Effect of serum on transfection by polyethylenimine/virus-like particle hybrid gene delivery vectors.Pharm Res. 2010 Nov;27(11):2457-65. doi: 10.1007/s11095-010-0238-z. Epub 2010 Aug 21. Pharm Res. 2010. PMID: 20730559
-
RNA replicon delivery via lipid-complexed PRINT protein particles.Mol Pharm. 2013 Sep 3;10(9):3366-74. doi: 10.1021/mp400190z. Epub 2013 Aug 21. Mol Pharm. 2013. PMID: 23924216 Free PMC article.
-
Engineered biological entities for drug delivery and gene therapy protein nanoparticles.Prog Mol Biol Transl Sci. 2011;104:247-98. doi: 10.1016/B978-0-12-416020-0.00006-1. Prog Mol Biol Transl Sci. 2011. PMID: 22093221 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical